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Abstract
Background: Preeclampsia and coronary-artery disease share risk factors, suggesting common pathophysiological
mechanisms. CX3CR1/CX3CL1 mediates leukocyte migration and adhesion and has been implicated in the pathophysiology
of several inflammatory diseases. M280/I249 variants of CX3CR1 are associated with an atheroprotective effect and reduced
endothelial dysfunction. The aim of this study was to search for an association between V249I and T280M polymorphisms of
CX3CR1, preeclampsia and endothelial dysfunction.
Methodology/Principal Findings: We explored these polymorphisms with real-time polymerase chain reaction in a case-
control study (184 white women with preeclampsia and 184 matched normotensive pregnant women). Endothelial
dysfunction biomarkers including von Willebrand factor, VCAM-1 and thrombomodulin, as well as the soluble form of
CX3CL1 were measured by enzyme-linked immunosorbent assays (ELISA). The I249 and M280 alleles were associated neither
with preeclampsia, nor with its more severe form or with endothelial injury. In contrast, we found a trend toward increased
CX3CL1 levels in preeclampsia patients, especially in early-onset- preeclampsia as compared to its level in later-onset-
preeclampsia.
Conclusions/Significance: This is the first study to characterize the CX3CR1 gene polymorphisms in patients with
preeclampsia. We found no differences in genotype or haplotype frequencies between patients with PE and normal
pregnancies, suggesting that maternal CX3CR1 V249I and T280M polymorphisms do not increase susceptibility to
preeclampsia. Further studies should be performed to directly evaluate the pathophysiological role of CX3CL1, a molecule
abundantly expressed in endometrium, which has been shown to stimulate human trophoblast migration.
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Introduction
Preeclampsia (PE) is a common complication occurring in about
2–7% of pregnancies, which is a major cause of perinatal and
maternal mortality and morbidity [1]. As we gain insight into the
pathophysiology of PE, placental ischemia and endothelial
dysfunction stand out as key factors [2]. The increase of many
markers of endothelial dysfunction, including thrombomodulin,
von Willebrand factor (VWF) and VCAM-1, has been repeatedly
reported in women with PE[2,3]. It has been suggested that release
of factors from the placenta in response to ischemia results in
endothelial dysfunction throughout the maternal circulation. It
also appears that the endothelial cell activation is reflective of a
generally enhanced inflammatory state [4].
CX3CL1/fractalkine (CX3CL1) is a unique CX3C chemokine
that is synthesized as a transmembrane molecule by endothelial
cells activated by proinflammatory cytokines [5]. Soluble
CX3CL1 can be released from the cell surface by proteolysis.
The cell-surface bound molecule serves as a potent adhesion
molecule while the secreted form has chemotactic activity. Its
expression in endothelial cells mediates both migration and
adhesion of CX3CR1-expressing cells [6]. CX3CR1, its 7-
transmembrane domain G-protein-coupled receptor, is expressed
on the surface of NK cells, monocytes and CD8+ T cells [6].
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6192Recently, CX3CL1 and CX3CR1 were both found in endometrial
cells [7]. Moreover, these authors also identified CX3CR1
expression on invading human trophoblasts [8] thus suggesting
an involvement of these molecules in the control of the utero-
placental vascularisation.
Two common single-nucleotide polymorphisms located in the
coding sequence of the CX3CR1 gene have been described: they
cause amino acid changes from valine to isoleucine at position 249
(V249I) and from threonine to methionine at position 280
(T280M) in the CX3CR1 protein [9]. These two polymorphisms
are in strong linkage disequilibrium, forming a common I249M280
haplotype. Their association with several inflammatory diseases
including arteriosclerosis and coronary artery disease has been
demonstrated [10,11,12]. Interestingly, the IM haplotype was
associated with a reduced risk of acute coronary events and
atherosclerosis, and with a decreased endothelial reactivity. V249I
and T280M involvement in these situations was explained by
functional mutated CX3CR1 analysis showing impaired receptor
expression and altered increased adhesive capacities [9,10,13].
Several studies have shown that women with a history of PE are
at increased risk of cardiovascular complications later in life
[14,15]. In addition, PE and coronary-artery disease share many
risk factors including hypertension, diabetes and dyslipidaemia
[16], suggesting common pathophysiological mechanisms: besides
impaired insulin sensitivity and inflammation, impaired microvas-
cular function has been described [17,18]. Finally, striking
similarities were reported between the atherosclerotic plaque and
atherosis lesions of spiral arteries in PE [19]. For these reasons, we
hypothesized that genetic variations of CX3CR1 might be
involved in PE as they are in coronary artery disease.
The aim of our study was to search for an association between
V249I and T280M polymorphisms of CX3CR1, PE and
endothelial dysfunction. We explored these polymorphisms in a
case-control study and evaluated endothelial dysfunction by
measuring several biomarkers including VWF, VCAM-1 and
thrombomodulin, as well as the soluble form of CX3CL1.
Materials and Methods
Ethics Statement
Written informed consent to take blood samples was obtained
from each woman before enrolment in our study which was
approved by the Ethics Committee (Comite ´ de Protection des
Personnes dans la Recherche Biome ´dicale, CCPPRB) of Ho ˆpital
Bichat-Claude Bernard (Paris). Written parental consent was also
obtained to take blood samples from newborns.
Study design and subjects
The ECLAXIR study is a multicenter case-control study for
which participants were recruited between May 2003 and October
2007 in 6 French university hospitals. The cases were 184 white
women with PE. Inclusion criteria were age $18 years, Caucasian
origin (defined as 4 grandparents born in Europe, or in the
Maghreb), gestational age $20 weeks, and PE defined according
to the definition of the American College of Obstetricians and
Gynecologists (ACOG) [20]. Patients with proteinuria occurring
before 20 gestational weeks were excluded. Controls were
normotensive pregnant women; for each PE patient, a control
matched for maternal age (62 years), gestational term (62 weeks)
and ethnic origin (European or Maghrebian) was included.
Controls who developed PE after enrolment were excluded from
the study and replaced by another subject matched with the
corresponding case.
PE was defined according to the ACOG [20] as elevated blood
pressure ($140/90 mm Hg) occurring after 20 weeks of gestation
with previously normal blood pressure, and proteinuria ($0.3 g in
a 24-hour urine specimen).
Severe PE was defined according to the ACOG [20] as the
presence of at least one of the following criteria: blood pressure
$160/110 mm Hg in 2 measurements 4 hours apart while the
patient is on bed rest; proteinuria $5 g in a 24-hour urine
specimen; oliguria of less than 25 mL per hour; cerebral or visual
disturbances; pulmonary oedema or cyanosis; epigastric pain;
impaired liver function defined as serum aspartate aminotransfer-
ase concentrations (ASAT) $70 IU/L; thrombocytopenia defined
as platelet count less than 100 Giga/L; fetal growth restriction
defined as a Z-score lower than 21.88. This value calculated
according to Salomon et al [21] is equivalent to a birth weight
below the third percentile for gestational age.
HELLP syndrome (Haemolysis, Elevated Liver enzymes, Low
Platelet count) was defined as the 3 following combined criteria
haemolysis (lactic dehydrogenase.600 IU/L, decreased hapto-
globin (,0.64 g/L) concentration or the presence of schizocytes in
the peripheral blood), thrombocytopenia (platelet count,100 -
Giga/L) and ASAT.70 IU/L.
PE was defined as early if gestational age at diagnosis was ,34
weeks.
Blood sampling and DNA extraction
Venous blood was collected, at the time of enrolment, in case
and control women into 1:10 final volume of 3.8% sodium citrate
and 15% K3EDTA solution. Platelet-poor plasma was obtained
from citrated blood by centrifugation at 2500 g for 20 minutes,
and aliquoted samples were stored at 280uC before being tested.
DNA extraction was carried out with K3EDTA blood and QIAmp
DNA Blood Midi Kit (QIAGEN, Courtaboeuf, France) according
to the manufacturer’s instructions.
At birth, cord blood was taken on K3EDTA in 182 newborns to
allow identification of their genetic status.
Screening for polymorphisms
The CX3CR1 gene V249I and T280M mutations were
identified using a real time polymerase chain reaction method
(PCR) [22] with slight modifications in the forward T280M primer
(59-AGGTGGTAAAGGTATCTTCTGAACTT-39) and allele
specific LNA Taqman probes: 59-FAM-ACTG[+A][+G]A[+C]-
G[+G]T[+T]GCAT-TAMRA-39 and 59-TET-TGACTG[+A][+
G]A[+T]G[+G]T[+T]GCAT-TAMRA-39 probes for Tyr
280 and
Met
280, respectively. Reactions were performed using the Rotor-
Gene 3000 (Corbett Research) with slight modifications for V249I:
3 min at 50uC and 10 min at 95uC of initial denaturation, followed
by 30 cycles with 20 sec at 95uC and 1 min at 64uC.
Laboratory assays
ELISA was used to assess protein levels: von Willebrand factor
antigen (AsserachromH vWF:Ag, STAGO, France), VCAM-1
(Human VCAM-1/CD106, R&D Systems, USA), thrombomo-
dulin (AsserachromH thrombomodulin, STAGO, France) and
soluble fractalkine (Human CX3CL1/Fracalkine, R&D Systems,
USA). For the soluble fractalkine ELISA kit, the lower detection
limit in plasma was 0.28 ng/mL with a coefficient of variability of
14.9% at 0.38 ng/mL.
Statistics
Qualitative values are reported as percentages and quantitative
values as mean6SD. Allelic frequencies were calculated by gene
CX3CR1 and Preeclampsia
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2 test
with 1 degree of freedom. Conditional logistic regression analysis
performed with SAS was used to compare qualitative and
quantitative variables between cases and controls; results were
expressed as odds ratios (ORs) with 95% confidence intervals
(CI)s. The relative contributions of V249I (VI+II versus VV) and
T280M (TM+MM versus TT) genotypes and that of combined
genotypes (versus the VV/TT reference combined genotype) to
the occurrence of PE were estimated after accounting for known
PE risk factors (nulliparity, pregestational BMI, pregestational
diabetes, multiple pregnancy, personal history of PE or thrombo-
sis, connective tissue disease or antiphospholipid antibody
syndrome). An adjustment for the other polymorphism was also
done (adjustment on M allele when evaluating V249I and
adjustment on I allele when evaluating T280M). The Student’s t
test or Kruskal-Wallis test were used to compare quantitative
variables among cases and controls. The program PHASE (version
2.1.1) was used to estimate frequencies of haplotypes [23]. The
relative contribution of V249I and T280M genotypes to the
severity and early onset of PE was estimated using conditional
logistic regression analysis after accounting for the other
polymorphism. The x
2 test was used to compare combined
genotype and haplotype frequencies among cases according to the
severity or the onset of PE. For comparisons of endothelial
markers, a linear regression analysis was used to account for
gestational age.
The prevalence of subjects carrying the I249 allele previously
detected in our control population [10] was equal to 49%. With
our sample size, the probability of detecting, at a=0.05 (2-tailed
test) an odds ratio of 0.55 for cases was 80%. The power of the
study was obtained with the software SPSS SamplePower2.
Results
Study population
Between May 2003 and October 2007, 223 cases and 203
control patients were enrolled. Fourteen control patients were
excluded for having developed PE after enrolment; five patients
with PE were excluded because of Middle Eastern or Asian
ethnic origins. Thus, 184 matched pairs of women were
analysed.
Table 1 shows general demographic, obstetrical and medical
characteristics of the study population. The 184 patients and
controls were matched for maternal age, gestational age, and
ethnic origin (141 pairs were from Europe, 40 pairs from the
Maghreb and 3 pairs had mixed European/Maghrebian
origins). Obesity (defined as a pre-pregnancy body mass index
[BMI].30 kg/m
2) was more frequent in the cases than in
controls (p=0.001). As expected, nulliparity (75.4 vs 53.8%),
multiple pregnancies (6.0 vs 0%), preterm delivery (68.9 vs
4.4%) and fetal growth retardation (12.5 vs 1.6%) were
significantly more frequent in cases than in controls. Personal
or familial history of PE was significantly more frequent in
cases. We also found a greater proportion of preeclamptic
women with a personal history of pregnancy loss before 22
weeks of gestation (20.3 vs 12.6%, p,0.03) or thrombosis (2.2
vs 0%; p=0.04). In the latter group, 3 patients had a history of
deep vein thrombosis and one of pulmonary embolism. By
Table 1. Demographic, obstetrical and medical characteristics of the study population.
Characteristics Cases (n=184) Controls (n=184) Odds ratio (95% Cl) p value
Age (years) - mean6SD 31.166.0 31.265.5 - -
Ethnicity
European % (n) 76.6 (141) 76.6 (141) - -
Maghrebian % (n) 21.7 (40) 21.7 (40) - -
European/Maghrebian % (n) 1.6 (3) 1.6 (3) - -
Gestational age (weeks) at enrolment mean6SD 33.963.8 33.763.8 - -
BMI before pregnancy.30 kg/m
2 % (n) 14.8 (27) 4.4 (8) 3.86 (1.68 to 8.86) ,0.01
Nulliparity % (n) 75.4 (138) 53.8 (99) 2.7 (1.67 to 4.35) ,0.01
Primipaternity % (n) 11.0 (20) 5.5 (10) 2.0 (0.090 to 4.45) 0.08
Multiple pregnancy % (n) 6.0 (11) 0 NA ,0.01
Preterm delivery (,37 GW) % (n) 68.9 (126) 4.4 (8) 59.5 (14.71 to 240.7) ,0.01
Fetal growth restriction % (n) 12.5 (24) 1.6 (3) 8.67 (2.56 to 29.31) ,0.01
History of preeclampsia
Personal % (n) 6.6 (12) 0 NA ,0.01
Familial % (n) 10.9 (20) 3.3 (6) 3.8 (1.42 to 10.18) ,0.01
History of venous thrombosis
Personal % (n) 2.2 (4) 0 NA ,0.05
Familial % (n) 10.3 (19) 5.4 (10) 2.1 (0.92 to 4.92) 0.08
Previous pregnancy loss before 22 GW % (n) 20.3 (37) 12.6 (23) 2.0 (1.08 to 3.72) ,0.03
Previous fetal death after 22 GW % (n) 1.1 (2) 1.7 (3) 0.7 (0.11 to 3.99) 0.65
Pregestational diabetes % (n) 2.8 (5) 0.6 (1) 4.99 (0.58 to 42.78) 0.14
Connective tissue disease or APLS % (n) 2.2 (4) 1.6 (3) 1.33 (0.30 to 5.96) 0.70
Some variation in number owing to missing data. BMI, body mass index; NA, not applicable; GW, gestation weeks; APLS, antiphospholipid syndrome. Fetal growth
restriction ,3d centile.
doi:10.1371/journal.pone.0006192.t001
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between cases and controls for pregestational diabetes, primi-
paternity, connective tissue disease or antiphospholipid antibody
syndrome.
In the cases, 80.4% of women had severe PE and 46.2% had
early-onset PE; 3.8% had a HELLP syndrome.
Preeclampsia and CX3CR1 polymorphisms
The frequencies of the V249I and T280M polymorphisms
showed no deviation from Hardy–Weinberg equilibrium. More-
over, no statistically significant difference in genotype frequencies
was found between cases and controls. The adjusted odds ratios
(ORs) associated with the I249 (VI+II versus VV genotype) and
M280 (TM+MM versus TT genotype) were 1.10 (95% confidence
interval [CI], 0.6–2.0; p=0.75) and 1.41 (95% CI, 0.7–2.8;
p=0.33), respectively (Table 2). Further adjustment for the other
polymorphism did not change the significance of the results (OR,
95% CI: 0.78, 0.3–1.8 [p=0.56] and 1.79, 0.7–4.6, [p=0.23],
respectively). The V249I and T280M polymorphisms are in
complete linkage disequilibrium and generate 6 combined
genotypes of the 9 theoretically possible (Table 3) and only 3
haplotypes (V249T280, I249T280 and I249M280). Indeed, all
subjects carrying allele M280 also carry allele I249, whereas in
some subjects, allele I249 is associated with allele T280. The
frequencies of combined genotypes and haplotypes were similar
between subjects with and without PE (Table 3). In some cases, the
genetic status of the newborns was identified. There was no
statistically significant difference either in the genotype frequencies
of the 2 polymorphisms in the newborns from PE (n=71) or
control mothers (n=112) (data not shown). Moreover, in controls,
the I and M allelic frequencies did not differ significantly between
European and Maghrebian ethnic groups (0.24 vs 0.31 for I allele,
and 0.13 vs 0.17 for M allele).
We then searched for an association between CX3CR1
genotypes and the severity of PE. Table 4 shows the frequencies
of the two CX3CR1 tested polymorphisms in the case group, as a
function of PE severity or time of onset. We did not find any
association of CX3CR1 V249I or T280M polymorphisms with
severe forms of PE or early-onset PE. Similar results were obtained
when using combined genotypes or haplotypes (Table 4).
Endothelial dysfunction
Table 5 shows mean values of endothelial lesion markers and of
soluble CX3CL1 that were measured in both groups. Correlation
between concentrations of these proteins and gestational age are
shown in Table 6. The plasma levels of VWF and VCAM-1 were
Table 2. Genotype frequencies of the V249I and T280M polymorphisms of the CX3CR1 gene in cases and controls.
Cases Controls Odds ratio 95% Cl p value
(n=184) (n=184)
V249I II % (n) 5.4 (10) 7.6 (14) 1.10* 0.60–2.03* 0.75*
VI % (n) 40.8 (75) 37.0 (68) 0.78** 0.34–1.79** 0.56**
VV % (n) 53.8 (99) 55.4 (102) 1 -
T280M MM % (n) 1.1 (2) 2.7 (5) 1.41* 0.70–2.84* 0.33*
TM % (n) 26.6 (49) 22.8 (42) 1.79** 0.69–4.61** 0.23**
TT % (n) 72.3 (133) 74.5 (137) 1 -
*ORs (95% CI, p values) adjusted for PE risk factors, associated with the (II+VI) versus the VV genotype and with the (MM+TM) versus the TT genotype.
**ORs (95% CI, p values) further adjusted for the other polymorphism.
doi:10.1371/journal.pone.0006192.t002
Table 3. Combined genotype and haplotype frequencies of the V249I and T280M polymorphisms of the CX3CR1 gene in cases
and controls.
Cases (n=184) Controls (n=184)
Combined genotype V249I T280M % (n) % (n) Adjusted OR (95% CI)*
VV TT 53.8 (99) 55.4 (102) 1
VI TT 17.9 (33) 17.4 (32) 0.8 (0.4–1.8)
VI TM 22.8 (42) 19.6 (36) 1.6 (0.7–3.4)
II TT 0.5 (1) 1.6 (3) NA
II MM 1.1 (2) 2.7 (5) NA
II TM 3.8 (7) 3.3 (6) 0.9 (0.2–4.7)
Haplotype % % OR (95% CI)
VT 74.2 73.9 1
IT 11.4 11.9 0.9 (0.6–1.5)
IM 14.4 14.1 1.0 (0.7–1.5)
Values are percentages of subjects (number) or haplotypes. NA not analysed because of small number of subjects (n#3 per group).
*ORs adjusted for PE risk factors.
doi:10.1371/journal.pone.0006192.t003
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(p,10
23) as was thrombomodulin (p=0.05). Soluble CX3CL1
levels were also increased in cases versus controls but this did not
reach statistical significance (p=0.08). Interestingly, the CX3CL1
levels did not vary with gestational age in the control group, but
showed a tendency to decrease in the PE group (p=0.05).
Moreover, CX3CL1 levels tended to be higher in patients with
very early-onset PE beginning at 25–29 weeks as compared with
controls analysed at the same gestational age (Table 6).
In order to search for an association between these laboratory
markers of endothelial injury and CX3CR1 genotypes, we
compared their mean values according to genotypes in the control
and the case groups. Our results showed no difference in the
concentration of these markers according to the V249I and
T280M genotypes in both groups of women (data not shown).
Moreover, there was no difference according, to the severity of PE
or to the gestational age at onset (data not shown).
Discussion
Our results strongly suggest that the occurrence of PE is
independent of CX3CR1 V249I or T280M polymorphisms of the
mother. Thus, despite several pathophysiological similarities and
risk factors between atherosclerosis and PE, we did not confirm
our hypothesis of a protective effect of genetic CX3CR1
polymorphisms in PE. The I249 and M280 alleles were associated
neither with PE, nor with its more severe form, nor with
endothelial injury evaluated by 3 laboratory markers.
Since the familial nature of PE has been known for many years,
various linkage and candidate gene studies have been carried out,
as recently reviewed by Mu ¨tze et al [24]. More than 50 candidate
genes have been studied, with 8 genes accounting for two thirds of
the studies [25]. Genome-wide searches identified several loci
suggestive of linkage but with inconsistent results. Recently, a
heterogeneity-based genome search meta-analysis identified ge-
netic regions (bins) associated with PE or severe PE [26]. In severe
PE, one of these bins was located in the 3q11.1-3q21.2 region of
chromosome 3, within the large cluster of chemokine receptors
[27,28]. Our study is the first to evaluate the role of the CX3CR1
gene.
Although the cause of preeclampsia remains unknown, three
main aetiological factors are involved, namely immune maladap-
tation, placental ischemia and increased oxidative stress [29].
Studies of the last two decades also showed that PE is a
multisystemic syndrome notably involving vasoconstriction, endo-
thelial dysfunction and increased inflammatory response [29].
Table 4. Genotype, combined genotype and haplotype frequencies of the V249I and T280M polymorphisms of the CX3CR1 gene
in the preeclampsia group, distributed according to severity and time of onset.
Severe PE NS PE OR* p Early PE Late PE OR* p
(n=148) (n=36) (95% CI) (n=85) (n=99) (95% CI)
Genotype V249I II % (n) 5.4 (8) 5.6 (2) 7.1 (6) 4.0 (4)
VI % (n) 43.2 (64) 30.6 (11) 3.1 (0.9–11.2) 0.08 45.9 (39) 36.4 (36) 1.9 (0.8–4.1) 0.12
VV % (n) 51.4 (76) 63.9 (23) 1 47.1 (40) 59.6 (59) 1
T280M MM % (n) 0.7 (1) 2.8 (1) 1.2 (1) 1.0 (1)
TM % (n) 27.0 (40) 25.0 (9) 0.4 (0.1–1.6) 0.19 29.4 (25) 24.2 (24) 0.8 (0.3–1.9) 0.66
TT % (n) 72.3 (107) 72.2 (26) 1 69.4 (59) 74.8 (74) 1
Combined genotype VI/TT % (n) 20.3 (30) 8.3 (3) 0.21
{ 21.2 (18) 15.2 (15) 0.29
{
VI/TM % (n) 23.0 (34) 22.2 (8) 24.7 (21) 21.2 (21)
VV/TT % (n) 51.4 (76) 63.9 (23) 47.1 (40) 59.6 (59)
Haplotype IT % 12.8 5.6 0.22
$ 14.1 9.1 0.20
$
IM % 14.2 15.3 15.9 13.1
VT % 73.0 79.2 70.0 77.8
Values are the percentage of subjects (number) and haplotypes. PE, preeclampsia. NS, non severe.
*ORs associated with the (II+VI) versus the VV genotype and with the (MM+TM) versus the TT genotype are adjusted for the other polymorphism.
{Chi
2 comparison for the 3 common combined genotypes.
$Chi
2 comparison for the 3 haplotypes.
doi:10.1371/journal.pone.0006192.t004
Table 5. Mean maternal plasma concentrations of VWF:Ag, Thrombomodulin, VCAM-1 and CX3CL1 in paired cases and controls.
n Cases n Controls Odds ratio (95% Cl) p
VWF:Ag (IU/dL) 157 363.16133.1 157 222.0692.7 1.13 (1.08–1.17) ,10
23
Thrombomodulin (ng/mL) 157 62.5629.4 157 54.4642.5 1.1 (1.00–1.21) 0.05
VCAM-1 (ng/mL) 156 1156.96430.5 156 647.46188.3 1.06 (1.04–1.08) ,10
23
CX3CL1 (ng/mL) 152 1.162.1 152 0.760.9 10.22 (0.78–134.03) 0.08
Values are mean6SD. Some variation in numbers due to missing data. VWF:Ag, von Willebrand factor antigen; VCAM-1, soluble vascular cell adhesion molecule-1;
CX3CL1 (soluble form). Odds ratios are calculated for 10 units of each parameter.
doi:10.1371/journal.pone.0006192.t005
CX3CR1 and Preeclampsia
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development of atherosclerosis. CX3CR1/CX3CL1 mediates a
mechanism of leukocyte capture, firm adhesion, and activation
which is independent of that induced by integrins and has been
implicated in the pathophysiology of several inflammatory
diseases, including renal diseases [30], allograft rejection [31],
and atherogenesis [32]. Several studies reported the atheropro-
tective effect of M280/I249 variants [10,11], although the specific
role of each variant was difficult to elucidate due to the strong
linkage disequilibrium between the two polymorphisms. The
function of CX3CR1 in atherosclerosis was further confirmed by
studies showing that inactivating the CX3CR1 gene reduced the
atherosclerotic lesion area as compared with wild mice in the
apoe2/2 background [33]. Interestingly, the peripheral mono-
nuclear blood cells of individuals with the CX3CR1 IM haplotype
adhered more strongly to membrane-CX3CL1 than did those of
CX3CR1-VT donors [13], thus suggesting that this excess
adhesion to CX3CL1-expressing endothelial cells might diminish
the extravasation of monocytes across the endothelial barrier. In
another study, binding experiments with peripheral mononuclear
blood cells from healthy donors showed that cells from
heterozygous VI individual expressed fewer CX3CR1 receptors
at the cell surface [10]. Although this hypothesis is attractive, we
did not find a molecular basis to support this mechanism, as PE
was not associated with the genetic polymorphisms whether
considered separately or as combined genotypes or haplotypes. We
did not find either an association between the VI/II or TM/MM
genotypes and the more severe form of PE (Table 4) or with the
degree of endothelial lesion measured using 3 well-known markers
of endothelial injury. Indeed, these marker levels were quite
similar according to genotype in cases as in controls. We also
studied the distribution of genotypes between the two distinct
forms of PE, the early-onset, placental and the late-onset, maternal
form [29]. We found no significant difference in genotype or
haplotype frequencies between these 2 forms. Ethnic groups of
cases and controls were carefully matched to remove this frequent
confounder.
In this study, we report for the first time soluble CX3CL1 levels
in normal and PE pregnancies. We found higher plasma
concentration of soluble CX3CL1 in cases versus controls at
diagnosis, although the difference fell short of statistical signifi-
cance. Moreover, CX3CL1 levels were higher in very early-onset
PE diagnosed between 25 and 29 weeks of gestational age as
compared to PE of later onset. These results however should be
considered with caution due to the large coefficient of variation of
the CX3CL1 assay.
The membrane-anchored form of CX3CL1 is primarily
expressed on the inflamed endothelium; recent work showed the
presence of its soluble form in the amniotic fluid of pregnant
women [34]. CX3CL1 is also abundant in entire endometrium
and placenta while its receptor (CX3CR1), is expressed on
trophoblast cell lines [8]. Human trophoblast migration was shown
to occur in response to CX3CL1 at the foetal-maternal interface
[8,35]. Interestingly, the mechanisms of embryo-endometrial
apposition/adhesion/invasion appear to be analogous to those of
leukocyte-endothelium rolling/adhesion/extravasation, as dis-
cussed by Dominguez et al [36]. The increase in soluble CX3CL1
which we observed in our study is a consequence of more
proteolysis of the membrane-anchored form. Whether this results
in less functional cellular CX3CL1 and less adhesion of
trophoblast cells to spiral arteries remains to be investigated.
Interestingly, a recent study showed that CX3CL1 confers an
essential survival signal to monocytes which might provide a
mechanistic explanation for its role in atherogenesis [37]. Our
results thus suggest the possible involvement in PE of CX3CL1
alterations (rather than CX3CR1). Alternatively, increased
CX3CL1 may represent a positive response of the endometrium
to placental ischemia. Indeed, CX3CL1 has been shown to have
pro-angiogenic properties [38] which may counteract the
deleterious anti-angiogenic effects of soluble flt1 and endoglin [39].
The recently identified expression of CX3CR1 by trophoblast
cells further suggests the importance of studying the fetal (or
paternal) genotype. Because cord blood was not always collected,
the number of cases and controls with fetal DNA was insufficient
to conclude in the present study.
In conclusion, this is the first study to characterize the CX3CR1
gene polymorphisms in patients with PE. We found no differences
in the allele or genotype frequencies between patients with PE and
normal pregnancies. Our study suggests that the CX3CR1 V249I
and T280M polymorphisms are not associated with the develop-
ment of PE in white women. In contrast, our results may suggest a
pathophysiological role for CX3CL1, a molecule abundantly
Table 6. Laboratory marker concentrations according to gestational age at enrolment.
Gestational age*
25 to 29 30 to 34 35 to 41 p
PREECLAMPSIA CASES n n n
VWF:Ag (IU/dL) 31 355.56116.1 70 379.56134.1 59 349.66136.1 0.35
Thrombomodulin (ng/mL) 31 58.4625.3 70 61.3629.2 59 65.0631.3 0.56
VCAM-1 (ng/mL) 31 1212.56446.3 69 1142.36445.8 59 1140.36398.4 0.72
CX3CL1 (ng/mL) 31 1.763.8 68 1.161.6 58 0.760.6 0.05
CONTROLS n n n
VWF:Ag (IU/dL) 38 176.3658.6 72 205.9680.8 68 260.6697.8 ,10
23
Thrombomodulin (ng/mL) 38 42.8617.7 72 57.0658.4 68 56.6620.1 ,10
23
VCAM-1 (ng/mL) 37 592.16158.3 72 612.76177.7 68 704.96186.0 ,10
23
CX3CL1 (ng/mL) 38 0.560.4 72 0.761.3 68 0.760.6 0.27
Enrolment was done at the onset of preeclampsia for cases, and at matched gestational age for controls.
Values are mean6SD. VWF:Ag, von Willebrand factor antigen; VCAM-1, soluble vascular cell adhesion molecule-1.
*gestational age is given in weeks.
doi:10.1371/journal.pone.0006192.t006
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signal for monocytes.
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